Skip to content
10-Q

Quarterly Report

REGENERON PHARMACEUTICALS, INC. REGN

0001804220-25-000022

← back to feed
Filed
Apr 29, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt Q1 2025 · Mar 31, 2025 $1.98B
Long Term Debt Q1 2025 · Dec 31, 2024 $1.98B
Current Liabilities Q1 2025 · Mar 31, 2025 $3.57B
Current Liabilities Q1 2025 · Dec 31, 2024 $3.94B
Total Liabilities Q1 2025 · Mar 31, 2025 $8.16B
Total Liabilities Q1 2025 · Dec 31, 2024 $8.41B
Current Assets Q1 2025 · Mar 31, 2025 $17.57B
Current Assets Q1 2025 · Dec 31, 2024 $18.66B
Total Assets Q1 2025 · Mar 31, 2025 $37.55B
Total Assets Q1 2025 · Dec 31, 2024 $37.76B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $2.49B
Cash And Equivalents Q1 2025 · Mar 31, 2024 $2.6B
Shares Diluted Q1 2025 · Mar 31, 2024 115.1M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $291.3M
Dividends Paid Q1 2025 · Mar 31, 2024 $0
Capex Q1 2025 · Mar 31, 2024 $133.9M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $1.51B
Stockholders Equity Q1 2025 · Mar 31, 2024 $26.99B
Stockholders Equity Q1 2025 · Dec 31, 2023 $25.97B
Eps Diluted Q1 2025 · Mar 31, 2024 $6.27
Eps Basic Q1 2025 · Mar 31, 2024 $6.70
Sga Expense Q1 2025 · Mar 31, 2024 $689M
Rd Expense Q1 2025 · Mar 31, 2024 $1.25B
Net Income Q1 2025 · Mar 31, 2024 $722M
Operating Income Q1 2025 · Mar 31, 2024 $751.4M
Revenue Q1 2025 · Mar 31, 2024 $3.15B